<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955940</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 18424-270</org_study_id>
    <nct_id>NCT02955940</nct_id>
  </id_info>
  <brief_title>An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib</brief_title>
  <official_title>An Open-Label, Multicenter, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib&#xD;
      plus background cancer therapy, or background cancer therapy alone to subjects from an&#xD;
      Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been&#xD;
      terminated.&#xD;
&#xD;
      This study will also provide another mechanism for reporting adverse events related to study&#xD;
      drug safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 30, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and types of adverse events and serious adverse events</measure>
    <time_frame>Maximum duration of every 2 months (maximum duration of 1 month for subjects receiving regorafenib) from enrollment through 30-37 days after end of treatment up to 24 months.</time_frame>
    <description>Subjects will be treated until disease progression or discontinuation criteria are met.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Colorectal Cancer (CRC)</condition>
  <condition>Breast Cancer</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study treatment for participants should be the same as the dosage from the parent study at the time the roll over protocol is initiated. Dose modifications are permitted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ruxolitinib plus background cancer therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study treatment for participants should be the same as the dosage from the parent study at the time the roll over protocol is initiated. Dose modifications are permitted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Background cancer therapy alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine and Regorafenib at the same dose provided in the parent study at the time of the rollover.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>5 mg BID</description>
    <arm_group_label>Ruxolitinib</arm_group_label>
    <arm_group_label>Ruxolitinib plus background cancer therapy</arm_group_label>
    <other_name>INCB018424</other_name>
    <other_name>Jakafi®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine at the same dose provided in the parent study at the time of the rollover.</description>
    <arm_group_label>Background cancer therapy alone</arm_group_label>
    <arm_group_label>Ruxolitinib plus background cancer therapy</arm_group_label>
    <other_name>Xeloda®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Regorafenib at the same dose provided in the parent study at the time of the rollover.</description>
    <arm_group_label>Background cancer therapy alone</arm_group_label>
    <arm_group_label>Ruxolitinib plus background cancer therapy</arm_group_label>
    <other_name>Stivarga®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of&#xD;
             ruxolitinib that has completed or been terminated.&#xD;
&#xD;
          -  Currently tolerating treatment in the parent protocol.&#xD;
&#xD;
          -  Currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus&#xD;
             background cancer therapy, or background cancer therapy alone, as determined by the&#xD;
             investigator.&#xD;
&#xD;
          -  Have at least stable disease, as determined by the investigator.&#xD;
&#xD;
          -  Has demonstrated compliance, as assessed by the investigator, with the parent study&#xD;
             protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has been permanently discontinued from study treatment in the parent study for any&#xD;
             reason.&#xD;
&#xD;
          -  Able to access ruxolitinib and/or background cancer therapy outside of the clinical&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fitzroy Dawkins, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Healthcare Hematology-Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology Pc.</name>
      <address>
        <city>Clifton Park</city>
        <state>New York</state>
        <zip>12065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renovatio Clinical</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, Md Anderson Cancer</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 3, 2016</study_first_submitted>
  <study_first_submitted_qc>November 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumors</keyword>
  <keyword>ruxolitinib</keyword>
  <keyword>regorafenib</keyword>
  <keyword>capecitabine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

